JP2024028452A5 - - Google Patents

Download PDF

Info

Publication number
JP2024028452A5
JP2024028452A5 JP2024002401A JP2024002401A JP2024028452A5 JP 2024028452 A5 JP2024028452 A5 JP 2024028452A5 JP 2024002401 A JP2024002401 A JP 2024002401A JP 2024002401 A JP2024002401 A JP 2024002401A JP 2024028452 A5 JP2024028452 A5 JP 2024028452A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
residue
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024002401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024028452A (ja
Filing date
Publication date
Priority claimed from JP2019052599A external-priority patent/JP2019162107A/ja
Application filed filed Critical
Publication of JP2024028452A publication Critical patent/JP2024028452A/ja
Publication of JP2024028452A5 publication Critical patent/JP2024028452A5/ja
Pending legal-status Critical Current

Links

JP2024002401A 2011-08-10 2024-01-11 セリアックスプルー病を治療するための組成物および方法 Pending JP2024028452A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161521899P 2011-08-10 2011-08-10
US61/521,899 2011-08-10
JP2019052599A JP2019162107A (ja) 2011-08-10 2019-03-20 セリアックスプルー病を治療するための組成物および方法
JP2021048356A JP2021094031A (ja) 2011-08-10 2021-03-23 セリアックスプルー病を治療するための組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021048356A Division JP2021094031A (ja) 2011-08-10 2021-03-23 セリアックスプルー病を治療するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2024028452A JP2024028452A (ja) 2024-03-04
JP2024028452A5 true JP2024028452A5 (enExample) 2024-10-23

Family

ID=46690751

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014525175A Active JP6342802B2 (ja) 2011-08-10 2012-08-10 セリアックスプルー病を治療するための組成物および方法
JP2017133615A Active JP6502428B2 (ja) 2011-08-10 2017-07-07 セリアックスプルー病を治療するための組成物および方法
JP2019052599A Pending JP2019162107A (ja) 2011-08-10 2019-03-20 セリアックスプルー病を治療するための組成物および方法
JP2021048356A Pending JP2021094031A (ja) 2011-08-10 2021-03-23 セリアックスプルー病を治療するための組成物および方法
JP2024002401A Pending JP2024028452A (ja) 2011-08-10 2024-01-11 セリアックスプルー病を治療するための組成物および方法

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2014525175A Active JP6342802B2 (ja) 2011-08-10 2012-08-10 セリアックスプルー病を治療するための組成物および方法
JP2017133615A Active JP6502428B2 (ja) 2011-08-10 2017-07-07 セリアックスプルー病を治療するための組成物および方法
JP2019052599A Pending JP2019162107A (ja) 2011-08-10 2019-03-20 セリアックスプルー病を治療するための組成物および方法
JP2021048356A Pending JP2021094031A (ja) 2011-08-10 2021-03-23 セリアックスプルー病を治療するための組成物および方法

Country Status (18)

Country Link
US (7) US9289473B2 (enExample)
EP (3) EP4023243A3 (enExample)
JP (5) JP6342802B2 (enExample)
CA (1) CA2882502A1 (enExample)
CY (1) CY1120877T1 (enExample)
DK (1) DK2718434T3 (enExample)
ES (2) ES2667418T3 (enExample)
HR (1) HRP20180687T1 (enExample)
HU (1) HUE037870T2 (enExample)
LT (1) LT2718434T (enExample)
NO (1) NO2718434T3 (enExample)
PL (2) PL3400958T3 (enExample)
PT (1) PT2718434T (enExample)
RS (1) RS57234B1 (enExample)
SI (1) SI2718434T1 (enExample)
SM (1) SMT201800249T1 (enExample)
TR (1) TR201806885T4 (enExample)
WO (1) WO2013023151A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037870T2 (hu) 2011-08-10 2018-09-28 Univ Washington Through Its Center For Commercialization Készítmények és módszerek lisztérzékenység kezelésére
EP3520808B1 (en) 2013-08-14 2021-04-21 University Of Washington Through Its Center For Commercialization Compositions for treating celiac sprue disease
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
BR112017026142A2 (pt) 2015-06-08 2018-08-14 Univ California composições e métodos para tratar doença sprue celíaca
AU2017380106B2 (en) * 2016-12-22 2024-05-09 Ew Nutrition Gmbh Stable protease variants
WO2020087017A1 (en) * 2018-10-26 2020-04-30 The Regents Of The University Of California Use of proteolytic enzymes to enhance protein bioavailability
US20240226248A9 (en) * 2018-10-26 2024-07-11 The Regents Of The University Of California Methods and compositions for improving protein hydrolysis
AU2021368118A1 (en) 2020-10-30 2023-05-11 The Regents Of The University Of California Compositions and methods for treating celiac sprue disease
WO2023147350A1 (en) 2022-01-26 2023-08-03 Digestiva, Inc. Blood glucose stabilizing methods and compositions
WO2025068987A1 (en) 2023-09-28 2025-04-03 Takeda Pharmaceutical Company Limited A method of producing a kumamolisin-as polypeptide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688229B1 (fr) 1992-03-09 1995-06-23 Ulice Soc Procede de synthese enzymatique d'esters alkyliques de peptides, produits ainsi obtenus et utilisation desdits produits.
JP2002078489A (ja) 2000-09-04 2002-03-19 Daiwa Kasei Kk セリン残基が活性発現に関与する新規酸性プロテアーゼ
US7303871B2 (en) 2002-02-14 2007-12-04 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7265093B2 (en) 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
WO2004045392A2 (en) 2002-11-20 2004-06-03 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
EP1600141B1 (en) 2004-05-24 2013-04-17 3M Deutschland GmbH Collagenolytic active enzyme containing compositions for the treatment of dental caries
EP1726643A1 (en) * 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
NZ591025A (en) 2008-08-21 2013-01-25 Alvine Pharmaceuticals Inc Formulation for oral administration of proteins
HUE037870T2 (hu) * 2011-08-10 2018-09-28 Univ Washington Through Its Center For Commercialization Készítmények és módszerek lisztérzékenység kezelésére
EP2788018B1 (en) 2011-12-06 2016-06-29 Fondazione Istituto Insubrico di Ricerca per la Vita New proteases able to hydrolyze gluten peptides and proteins at acidic ph, from the actinomycete actinoallomurus
EP3520808B1 (en) 2013-08-14 2021-04-21 University Of Washington Through Its Center For Commercialization Compositions for treating celiac sprue disease

Similar Documents

Publication Publication Date Title
JP2024028452A5 (enExample)
JP2025004002A5 (enExample)
JP2022062113A5 (enExample)
JP2025066711A5 (enExample)
KR100316347B1 (ko) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
JP2002510494A5 (enExample)
JPH09322781A5 (enExample)
CA2400295A1 (en) Modified factor viii
CA2337100A1 (en) Polypeptides of lymphodendritic cell adhesion molecules (ldcams) and polynucleotides encoding the same
JP2003516731A5 (enExample)
JPWO2020072821A5 (enExample)
CA2179909A1 (en) Ligand that binds fas antigen
JP2005509420A5 (enExample)
JP2005519617A5 (enExample)
JP2004500088A5 (enExample)
JP2008545393A5 (enExample)
JP2002517193A5 (enExample)
WO2023155901A1 (en) Mutant cytidine deaminases with improved editing precision
MX2009004985A (es) Secuencias para activar la expresión y control de las modificaciones de post-traducción de un polipéptido recombinante.
JPWO2021072298A5 (enExample)
JP2004532037A5 (enExample)
US5888766A (en) Method for producing recombinant human myoglobin
JPH05501054A (ja) 内部翻訳開始の防止
RU2003109439A (ru) Миметические пептиды для эпитопа аполипопротеина в-100, их конкатемер и модифицированные пептиды и вакцина, содержащая их
JPS6041487A (ja) 酵母発現系でのアルフア因子配列の使用